UMSC01 not checked

Ever Supreme Bio Technology Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“UMSC01 cells will be IC infusion followed by IV infusion with 24 months of follow up after treatment.”In the company’s words, NCT06147986 on ClinicalTrials.gov
Tested for
ST Elevation Myocardial Infarction, COVID-19 Infection, Multiple Sclerosis
Main trialPhase 2
“This phase IIa study is to identify the efficacy and safety of IC(intracoronary) and IV(Intravenous) administrations of UMSC01 in patients with STEMI . This product is a new cell therapy product for treating AMI and produced by Ever Supreme Bio Technology Co., Ltd in Taiwan. The previous Phase I, open-label, single arm, single center study was conducted to evaluate the safety and to explore the efficacy of UMSC01 in subjects with STEMI via intracoronary administration followed by intravenous infusion. This first-in-human Phase I study of UMSC01 was completed on August 2nd, 2021. Among 8…”In the company’s words, NCT06147986 on ClinicalTrials.gov

Other drugs for ST Elevation Myocardial Infarction

All 7 drugs for ST Elevation Myocardial Infarction

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 24 Jun 2027 Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
Phase 1/2Active, not recruiting 31 Dec 2027 Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19
Phase 1/2Recruiting 31 Oct 2028 Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
Phase 1Completed 2 Aug 2021 Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction
Phase 1Completed 23 Jan 2026 Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow UMSC01

Following is part of Solo: you see every change to UMSC01 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in